Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$170.68 ▲ +5.07
(+3.06%)
MKT CAP: $211.64B • VOL: 11.43M
52W L $117 52W H $176
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$143
MEDIAN
$191
MEAN
$195
HIGH
$232
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE GILD TAPE
GILD // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $206.52 | $196.28 | 2025-02-14 | $155.32 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $215.06 | $201.40 | 2025-02-06 | $160.44 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $194.58 | $187.75 | 2025-01-29 | $163.85 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $174.09 | — | 2025-01-17 | $167.27 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $150.20 | $162.15 | 2025-01-09 | $151.91 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $203.11 | $177.51 | 2024-12-18 | $148.49 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $165.56 | $172.39 | 2024-12-04 | $158.73 | -4.3% | 48% | C |